RVNC

Revance Therapeutics, Inc. (RVNC) | Rumor.io

Revance Therapeutics

RVNC

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about RVNC?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 6

Revance Therapeutics, Inc. ($RVNC) has received a superior proposal from Teoxane SA to acquire the company for $3.60 per share in cash, representing a 16% premium over the previous agreement with Crown Laboratories.
The proposed acquisition price is $3.60 per share, which is higher than the previously agreed-upon price of $3.10 per share.
Revance Therapeutics' stock price has increased following the announcement of the superior proposal, with some investors speculating about the potential implications of the deal.

Generated by AI

Sentiment

Of the messages about RVNC that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	75% +18.74
Bearish	—	—	—	25% -18.74

Bullish· Aug 12

$RVNC is a good buy opportunity, with a potential for significant price increase.
The company's low market capitalization and large short position make it an attractive target for a potential buyout.
The buyout announcement at $6.66 per share is a significant positive development for the stock, with some investors already seeing potential for further gains.

Bearish· Aug 12

Revance Therapeutics, Inc. (RVNC) was acquired at a 90% premium to its IPO price, potentially indicating a poor investment opportunity.
The company's management has been criticized for mismanaging the business and failing to compete with established brands in the aesthetics space, leading to significant losses for shareholders.
The acquisition of RVNC by a competitor was seen as a major disappointment for long-term investors, with many having purchased the stock at higher prices, resulting in substantial losses.

Generated by AI

Topics

Of the messages about RVNC that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	0%
Macro	—	—	—	0%
Earnings	—	—	—	0%
Controversies	—	—	—	18.75%
Announcements	—	—	—	81.25%
Analysts	—	—	—	0%

Earnings· Feb 26

Revance Therapeutics, Inc. (RVNC) missed earnings by $0.15 and revenue expectations.
The company reported FQ4 earnings of -$1.12 EPS and $0.49M in revenue.
RVNC missed the Estimize EPS consensus by 20 cents and revenue consensus by $2.34M.

Analysts· Sep 9

Cowen analyst Ken Cacciatore raised the price target on RVNC to $65.00, citing the approval of Daxxify and its potential for a steep launch ramp exceeding $1B.
Analysts have raised the price target on RVNC, with targets ranging from $30 to $65, and a consensus buy rating of 84% among 16 analysts.
Several analysts, including Cowen, Mizuho, Needham, and Barclays, have raised their price targets on RVNC, with some maintaining a Buy or Overweight rating.

Announcements· Oct 28

Revance Therapeutics ($RVNC) and Teoxane have settled their dispute, with Teoxane becoming the exclusive distributor for Revance's Daxxify in Australia and New Zealand.
The settlement has led to an extension of the deadline for Crown's tender offer to buy all of Revance's outstanding shares to November 1.
The ongoing discussions between Revance and Crown may lead to a price cut on the merger, with the current spread offering a potential 13.9% return if the deal closes at $6.66.

Generated by AI

Community

Of the messages about RVNC, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	3.51%
Newcomers	—	—	—	96.49%

Regulars· Aug 12

The $6.66 per share buyout price for RVNC is significantly lower than the $16 IPO price, and regulars are questioning the company's ability to compete with Botox.
Despite strong clinical results for DAXXIFY, RVNC's management is being criticized for destroying shareholder value and mismanaging the company, leading to a lower-than-expected buyout price.
Some regulars are speculating that there may be another bidder interested in RVNC, causing the stock to rise towards the deal price, and potentially indicating that the deal may not be as done as it seems.

Newcomers· Oct 28

$RVNC is expected to see a price cut, likely by 10% or more, as a result of the merger consideration change.
The merger agreement may be delayed due to discussions with the buyer parties, which could result in further changes to the offer price.
$RVNC has experienced a significant premarket price spike, with a 20.85% increase in value, and is setting up for another potential upward movement.

Generated by AI

News

PanOxyl’s “Here For It All” Campaign Is Changing the Way Brands Talk About Acne

The new “Here For It All” campaign from PanOxyl is built around a quieter reality: the mental space acne takes up, and the relief that comes when people can stop thinking about it so much.

2mo agoUSA Today

Also Discussed

Investors talking about RVNC also mention

#	Name	Attention
1	Evolus Inc.EOLS	0%0
2	Enanta Pharmaceuticals, Inc.ENTA	0%0
3	Heron Therapeutics, Inc.HRTX	0%+0
4	BPMC - Blueprint Medicines Corporation	——
5	Neurocrine Biosciences, Inc.NBIX	0%new
6	MRTX - Mirati Therapeutics, Inc.	——
7	Roivant Sciences Ltd.ROIV	0%new
8	DCPH - Deciphera Pharmaceuticals, Inc.	——
9	FOLD - Amicus Therapeutics, Inc.	——
10	Fennec Pharmaceuticals Inc.FENC	0%0